Prediction of Residual Risk by Ceramide-Phospholipid Score in Patients With Stable Coronary Heart Disease on Optimal Medical Therapy.

Abstract	Background Identification of patients with stable coronary heart disease who are at significant residual risk could be helpful for targeted prevention. Our aim was to determine the prognostic value of the recently introduced ceramide- and phospholipid-based risk score, the Cardiovascular Event Risk Test (CERT2), in patients with stable coronary heart disease on optimal medical therapy and to identify biological processes that contribute to the CERT2 score. Methods and Results Plasma samples (n=11 222) obtained from the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) trial were analyzed using a tandem liquid chromatography-mass spectrometry method. STABILITY was a trial in patients with stable coronary heart disease randomized to the lipoprotein-associated phospholipase A2 inhibitor darapladib or placebo on optimized medical therapy at baseline, with a median follow-up of 3.7 years. Hazard ratios per SD for the CERT2 risk score were 1.32 (95% CI, 1.25-1.39) for major adverse cardiovascular event, 1.47 (95% CI, 1.35-1.59) for cardiovascular death, 1.32 (95% CI, 1.16-1.49) for stroke, 1.23 (95% CI, 1.14-1.33) for myocardial infarction, and 1.56 (95% CI, 1.39-1.76) for hospitalization due to heart failure, when adjusted for traditional cardiovascular risk factors. CERT2 showed correlation (P<0.001, r>0.2) with inflammatory markers high-sensitivity C-reactive protein, interleukin 6, the heart failure marker N-terminal pro-B-type natriuretic peptide, and low-density lipoprotein cholesterol. After also adjusting for levels of other prognostic biomarkers, the CERT2 score was still independently related to the risk of cardiovascular death but not to nonfatal events. Conclusions The CERT2 risk score can detect residual risk in patients with stable coronary heart disease and is associated with biomarkers indicating inflammation, myocardial necrosis, myocardial dysfunction, renal dysfunction, and dyslipidemia. REGISTRATION URL: https://www.clinicaltrials.gov. Unique identifier: NCT00799903.
Authors	Mika Hilvo, Lars Wallentin, Tatevik Ghukasyan Lakic, Claes Held, Dimple Kauhanen, Antti Jylhä, Johan Lindbäck, Agneta Siegbahn, Christopher B Granger, Wolfgang Koenig, Ralph A H Stewart, Harvey White, Reijo Laaksonen, STABILITY Investigators
Journal	Journal of the American Heart Association (J Am Heart Assoc) Vol. 9 Issue 10 Pg. e015258 (05 18 2020) ISSN: 2047-9980 [Electronic] England
PMID	32375553 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial)
Chemical References	Biomarkers Cardiovascular Agents Ceramides Phospholipids
Topics	Aged Biomarkers (blood) Cardiovascular Agents (therapeutic use) Ceramides (blood) Chromatography, Liquid Coronary Disease (blood, diagnosis, drug therapy, mortality) Female Health Status Indicators Humans Male Mass Spectrometry Middle Aged Phospholipids (blood) Predictive Value of Tests Risk Assessment Risk Factors Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!